Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876649 · ClinicalTrials.gov registry record · Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
A Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 787
- Enrollment target
- 20
- Study locations
NCT06876649 is a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 787 participants, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (342% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06876649, a Phase 4 study of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 787 participants
- Enrollment target
- 20
- Study locations
Study Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.
Conditions Studied
Interventions
- DRUG Pirtobrutinib
Study Locations (20)
New York
- Cayuga Cancer Center - Ithaca
- Northwell Health - Lake Success
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
Florida
- Cancer Specialists, LLC - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
- Florida Cancer Specialists - Sarasota
Georgia
- The Emory Clinic - Atlanta
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic- Minnesota - Rochester
Nebraska
- University Of Nebraska Medical Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 787 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2032-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06876649
The ClinicalTrials.gov registry entry for NCT06876649 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 787 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 178-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (342% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06876649 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06876649 about?
NCT06876649 is a clinical study titled "A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib". The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies...
What is the current status of trial NCT06876649?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 787 participants. The study started on 2025-05-20. Estimated completion is 2032-12.
What conditions does trial NCT06876649 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT06876649?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06876649?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876649 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RECRUITING · Phase 4
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
RECRUITING
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.